WRBY vs. BLCO, RXST, STAA, EYE, LUCY, ALC, COO, VKTX, ENSG, and MASI
Should you be buying Warby Parker stock or one of its competitors? The main competitors of Warby Parker include Bausch + Lomb (BLCO), RxSight (RXST), STAAR Surgical (STAA), National Vision (EYE), Innovative Eyewear (LUCY), Alcon (ALC), Cooper Companies (COO), Viking Therapeutics (VKTX), The Ensign Group (ENSG), and Masimo (MASI). These companies are all part of the "medical" sector.
Bausch + Lomb (NYSE:BLCO) and Warby Parker (NYSE:WRBY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking.
Bausch + Lomb has a net margin of -7.81% compared to Bausch + Lomb's net margin of -7.89%. Warby Parker's return on equity of 3.60% beat Bausch + Lomb's return on equity.
Bausch + Lomb and Warby Parker both received 24 outperform votes by MarketBeat users. However, 38.71% of users gave Bausch + Lomb an outperform vote while only 32.88% of users gave Warby Parker an outperform vote.
In the previous week, Warby Parker had 5 more articles in the media than Bausch + Lomb. MarketBeat recorded 7 mentions for Warby Parker and 2 mentions for Bausch + Lomb. Warby Parker's average media sentiment score of 0.97 beat Bausch + Lomb's score of 0.51 indicating that Bausch + Lomb is being referred to more favorably in the media.
Bausch + Lomb presently has a consensus target price of $19.45, indicating a potential upside of 25.68%. Warby Parker has a consensus target price of $16.50, indicating a potential downside of 3.00%. Given Warby Parker's stronger consensus rating and higher possible upside, equities analysts plainly believe Bausch + Lomb is more favorable than Warby Parker.
Warby Parker has lower revenue, but higher earnings than Bausch + Lomb. Warby Parker is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.
Bausch + Lomb has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Warby Parker has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.
11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 93.2% of Warby Parker shares are owned by institutional investors. 26.6% of Warby Parker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Bausch + Lomb beats Warby Parker on 10 of the 17 factors compared between the two stocks.
Get Warby Parker News Delivered to You Automatically
Sign up to receive the latest news and ratings for WRBY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WRBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Warby Parker Competitors List
Related Companies and Tools
